Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 4.5% – Should You Sell?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH)’s share price dropped 4.5% on Thursday . The stock traded as low as $19.84 and last traded at $19.84. Approximately 4,920 shares traded hands during mid-day trading, a decline of 98% from the average daily volume of 204,708 shares. The stock had previously closed at $20.77.

Wall Street Analyst Weigh In

DNTH has been the subject of several research analyst reports. Oppenheimer upped their price objective on Dianthus Therapeutics from $48.00 to $52.00 and gave the company an “outperform” rating in a report on Monday, November 11th. Robert W. Baird initiated coverage on Dianthus Therapeutics in a report on Friday, July 26th. They issued an “outperform” rating and a $58.00 price objective for the company. Baird R W upgraded Dianthus Therapeutics to a “strong-buy” rating in a report on Friday, July 26th. Raymond James upped their price objective on Dianthus Therapeutics from $51.00 to $56.00 and gave the company an “outperform” rating in a report on Friday, November 8th. Finally, Wedbush cut their price objective on Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating for the company in a report on Friday, August 9th. Eight investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $46.43.

Dianthus Therapeutics Price Performance

The firm has a market capitalization of $661.20 million, a PE ratio of -8.94 and a beta of 1.84. The firm has a fifty day moving average price of $27.10 and a 200 day moving average price of $26.59.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.15). The business had revenue of $2.17 million for the quarter, compared to analyst estimates of $1.07 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. On average, sell-side analysts expect that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of DNTH. Quest Partners LLC increased its position in Dianthus Therapeutics by 112,400.0% in the 3rd quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock worth $31,000 after purchasing an additional 1,124 shares during the last quarter. SG Americas Securities LLC acquired a new position in Dianthus Therapeutics in the 2nd quarter worth about $112,000. The Manufacturers Life Insurance Company acquired a new position in Dianthus Therapeutics in the 2nd quarter worth about $236,000. Fred Alger Management LLC increased its position in Dianthus Therapeutics by 52.5% in the 3rd quarter. Fred Alger Management LLC now owns 9,633 shares of the company’s stock worth $264,000 after purchasing an additional 3,316 shares during the last quarter. Finally, WINTON GROUP Ltd acquired a new position in Dianthus Therapeutics in the 2nd quarter worth about $265,000. 47.53% of the stock is owned by institutional investors and hedge funds.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.